Evidence map›Paper›PMID 30323621›Full record

ArticleOncoTargets and therapy2018

Radix

Xiaowei Wu, Na Yu, Yuping Zhang, Yuanning Ye, Wenrong Sun, Lei Ye, Huimin Wu, Zhao Yang, Lin Wu, Fangyu Wang

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Xiaowei WuDepartment of Gastroenterology and Hepatology, Jinling Hospital, Nanjing, China.
Na YuDepartment of Gastroenterology and Hepatology, Jinling Hospital, Nanjing, China.
Yuping ZhangDepartment of Gastroenterology and Hepatology, Jinling Hospital, Southern Medical University, Guangzhou, China.
Yuanning YeDepartment of Gastroenterology and Hepatology, Jinling Hospital, Southern Medical University, Guangzhou, China.
Wenrong SunDepartment of Gastroenterology and Hepatology, Jinling Hospital, Nanjing, China.
Lei YeDepartment of Gastroenterology and Hepatology, Jinling Hospital, Nanjing, China.
Huimin WuDepartment of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China, wangfy2018@126.com.
Zhao YangDepartment of Gastroenterology and Hepatology, Jinling Hospital, Southern Medical University, Guangzhou, China.
Lin WuDepartment of Gastroenterology and Hepatology, Jinling Hospital, Nanjing, China.
Fangyu WangDepartment of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China, wangfy2018@126.com.
Nanjing General Hospital of Nanjing Military Command · CNSouthern Medical University · CNNanjing Medical University · CNJinling Institute of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadix MATERIALS AND

methodsCell Counting Kit-8, colony formation, and flow cytometry assays were performed to evaluate the proliferation of RTHF-treated colon tumor cells. Migration and invasion capacities were also tested by cell wound scratch assay and Transwell invasion assay. Moreover, the antitumor effects of RTHF on azoxymethane/dextran sulfate sodium-induced colitis-related CRC were investigated in C57BL/6 mice. In addition, Western blot and/or quantitative reverse transcription polymerase chain reaction analysis were used to evaluate the expressions of Lgr5, Cyclin D1, c-Myc, and E-cadherin.

resultsThese experiments showed that RTHF could decrease the cell growth kinetics and clone-forming capacity. RTHF could also dose dependently induce cell cycle arrest at G0/G1 phase and inhibit epithelial-mesenchymal transition process. Furthermore, downregulation of β-catenin activation and downstream protein expression were detected in CRC cells after being treated with RTHF. RTHF daily gavage suppressed the number and size of CRC in mice and inhibited Lgr5 and Cyclin D1 expressions in tumor tissue.

conclusionIn conclusion, RTHF treatment inhibits colorectal tumor growth, decreases Wnt/β-catenin pathway activity, and downregulates target genes' expression.

Indexed as

colorectal cancerflavonemigrationproliferationradix Tetrastigma hemsleyaniWnt/β-catenin

Identifiers

PMID30323621
PMCPMC6177378
OpenAlexW2895694580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.